We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.80 | 0.11% | 1,707.00 | 1,707.00 | 1,707.40 | 1,708.60 | 1,699.40 | 1,701.60 | 418,076 | 09:41:22 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.25 | 70.23B |
LONDON-- GlaxoSmithKline PLC (GSK.LN) said Tuesday that it and Merck & Co. Inc. (MRK) will trial a combination of two separate drugs as a potential cancer treatment.
The companies will commence human trails to evaluate Glaxo's investigational immunotherapy GSK3174998 as monotherapy in combination with Merck's anti-PD-1 therapy Keytruda in patients with tumors that have progressed after standard treatment.
Shares of Glaxo at 1227 GMT trading 0.04% lower at 1,397 pence.
Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 03, 2015 07:45 ET (12:45 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions